|View printer-friendly version|
Spring Bank Announces Additional Inarigivir Results at AASLD Conference
*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted
*New data from ACHIEVE trial demonstrates that increased baseline serum IP-10, a marker of immune activation in HBV, is a positive predictor for anti-viral response to inarigivir
In the poster of distinction presentation titled Inarigivir is a Novel Selective Inhibitor of the HBV Replicase Complex In Vitro, Professor
In the oral presentation titled Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response, Professor
“The dose dependent anti-viral response to inarigivir has continued through the 100mg daily dose cohort and the HBsAg reduction in almost 30% of patients treated in the first three cohorts is unique to inarigivir amongst approved and investigational oral HBV anti-virals. Interestingly, new data from the ACHIEVE trial on predictors provides evidence that HBsAg burden ( > 4log10), a key inhibitor of the immune response, reduces anti-viral efficacy and that increased serum IP-10, a marker of immune activation in HBV, is a positive predictor for anti-viral response as previously reported for interferon therapy,” stated Professor Yuen.
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date after the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.